Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. Margherita Nosadini , Michael Eyre , Thea Giacomini , Massimiliano Valeriani , Marida Della Corte , Andrea D Praticò , Pietro Annovazzi , Ramona Cordani , Duccio Maria Cordelli , Giovanni Crichiutti , Gabriella Di Rosa , Valentina Dolcemascolo , Anna Fetta , Elena Freri , Paolo Gallo , Matteo Gastaldi , Tiziana Granata , Luisa Grazian , Raffaele Iorio , Martina Lombardini , Monica Margoni , Sara Mariotto , Sara Matricardi , Federico Melani , Nardo Nardocci , Laura Papetti , Alice Passarini , Francesco Pisani , Chiara Po' , Marco Puthenparampil , Francesca Ragona , Salvatore Savasta , Sabrina Siliquini , Irene Toldo , Alessandra Tozzo , Emanuela Claudia Turco , Antonio Varone , Alberto Vogrig , Luigi Zuliani , Samuela Bugin , Sara Rossato , Alessandro Orsini , Gaetano Cantalupo , Maria Margherita Mancardi , Michela Ada Noris Ferilli , Thomas Foiadelli , Stefano Sartori Neurology(R) neuroimmunology & neuroinflammation（2023）
摘要
At first attack of pediatric MOGAD, early immunotherapy, longer duration of corticosteroid treatment, and abnormal optic nerves on MRI seem associated with lower risk of relapse, whereas higher disease severity is associated with greater risk of final disability (EDSS ≥ 1).
更多 查看译文
关键词
pediatric mogad, longer corticosteroid treatment, immunotherapy
AI 理解论文
溯源树
样例
